Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peripheral artery disease, biomarkers, and darapladib.
Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, Trivedi T, Zalewski A, Mohler ER 3rd. Berger JS, et al. Among authors: zalewski a. Am Heart J. 2011 May;161(5):972-8. doi: 10.1016/j.ahj.2011.01.017. Am Heart J. 2011. PMID: 21570531 Free PMC article. Clinical Trial.
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators. Mohler ER 3rd, et al. Among authors: zalewski a. J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079. J Am Coll Cardiol. 2008. PMID: 18436114 Free article. Clinical Trial.
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. Wilensky RL, et al. Among authors: zalewski a. Nat Med. 2008 Oct;14(10):1059-66. doi: 10.1038/nm.1870. Epub 2008 Sep 21. Nat Med. 2008. PMID: 18806801 Free PMC article.
Site-specific atherogenic gene expression correlates with subsequent variable lesion development in coronary and peripheral vasculature.
Mohler ER 3rd, Sarov-Blat L, Shi Y, Hamamdzic D, Zalewski A, Macphee C, Llano R, Pelchovitz D, Mainigi SK, Osman H, Hallman T, Steplewski K, Gertz Z, Lu MM, Wilensky RL. Mohler ER 3rd, et al. Among authors: zalewski a. Arterioscler Thromb Vasc Biol. 2008 May;28(5):850-5. doi: 10.1161/ATVBAHA.107.154534. Epub 2008 Feb 14. Arterioscler Thromb Vasc Biol. 2008. PMID: 18276914
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.
Lp-PLA(2) Studies Collaboration; Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lp-PLA(2) Studies Collaboration, et al. Lancet. 2010 May 1;375(9725):1536-44. doi: 10.1016/S0140-6736(10)60319-4. Lancet. 2010. PMID: 20435228 Free PMC article.
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Lp-PLA2 Studies Collaboration; Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Koenig W, Sacco R, Elkind M, Talmud P, Rimm E, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Packard C, Wassertheil-Smoller S, Ridker P, Ballantyne C, Cannon CP, Cushman M, Danesh J, Gu D, Hofman A, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Thompson S, Walker M, Watson S, Wood A. Lp-PLA2 Studies Collaboration, et al. Among authors: zalewski a. Eur J Cardiovasc Prev Rehabil. 2007 Feb;14(1):3-11. doi: 10.1097/01.hjr.0000239464.18509.f1. Eur J Cardiovasc Prev Rehabil. 2007. PMID: 17301621
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A; Integrated Biomarker and Imaging Study-2 Investigators. Serruys PW, et al. Among authors: zalewski a. Circulation. 2008 Sep 9;118(11):1172-82. doi: 10.1161/CIRCULATIONAHA.108.771899. Epub 2008 Sep 1. Circulation. 2008. PMID: 18765397 Clinical Trial.
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group. Ratner RE, et al. Among authors: zalewski a. Am Heart J. 2008 Dec;156(6):1074-9. doi: 10.1016/j.ahj.2008.07.025. Epub 2008 Oct 11. Am Heart J. 2008. PMID: 19033001 Clinical Trial.
267 results